Simavita Limited

Results of Government SIM(R) Trial in Denmark - Seite 2

The objective of the evaluation was to determine whether the use of SIM® assessments would result in an accurate, systematic approach to incontinence assessment, and deliver an optimised and person-centred consumption of incontinence pads.

Results

The SIM® 72 hour assessment was conducted across a group of residents. The trial focused on three elements: the resident, the nursing staff and the IT system. Significant outcomes from the trial as expressed in the report were as follows:

• The customer expressed the view that the SIM® system is easy to work with.
  
  
• 60% of the residents assessed are now wearing a smaller sized pad during the day.
  
  
• Over 25% of the residents assessed are now using a smaller sized pad during the night.
  
  
• Post assessment, a reduction in the occurrence of urinary tract infection amongst the residents was observed.
  
  
• Post assessment, a reduction in the number of falls amongst these residents was also observed.

These observations should result in a lower total cost of consumables used (i.e. the use of fewer and smaller pads), as well as the potential to improve clinical outcomes and reduce key risks in respect of falls and urinary tract infections (UTIs). Both UTIs and falls are common triggers for entry into acute care (hospitals), which in turn translates to higher costs to the healthcare sector. Additionally, UTIs and falls create serious clinical and personal complexities for the elderly.

"The observations from this Danish trial are consistent with our experience in other markets and we are absolutely delighted that such positive clinical and commercial outcomes were identified. These results now provide an excellent platform for a broader Danish roll out, as well as an important reference point for other European countries", commented Simavita CEO, Mrs. Philippa Lewis.

As a result of the successful trial and the evaluation report, momentum is building in Denmark with further Danish Municipalities positioned to commence trials of the SIM® system technology.

For further information, see our website (www.simavita.com) or contact the persons outlined below.

About Simavita

Simavita is a medical device company that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM® platform technology which is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.